MedinCell S.A. (EPA:MEDCL)
34.58
+0.68 (2.01%)
Oct 20, 2025, 1:44 PM CET
MedinCell Employees
MedinCell had 131 employees as of March 31, 2025. The number of employees decreased by 3 or -2.24% compared to the previous year.
Employees
131
Change (1Y)
-3
Growth (1Y)
-2.24%
Revenue / Employee
€211,656
Profits / Employee
€140,748
Market Cap
1.12B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 131 | -3 | -2.24% |
Mar 31, 2024 | 134 | 3 | 2.29% |
Mar 31, 2023 | 131 | -8 | -5.76% |
Mar 31, 2022 | 139 | 1 | 0.72% |
Mar 31, 2021 | 138 | 5 | 3.76% |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
EssilorLuxottica Société anonyme | 153,498 |
emeis Société anonyme | 83,494 |
Sanofi | 82,878 |
Eurofins Scientific SE | 62,696 |
Clariane SE | 61,798 |
bioMérieux | 14,754 |
Sartorius Stedim Biotech | 9,901 |
Virbac | 6,365 |
MedinCell News
- 9 days ago - Teva : FDA Grants Expanded Approval For UZEDY To Treat Bipolar I Disorder In Adults - Nasdaq
- 4 weeks ago - Medincell Reports Positive Phase 3 Safety Data For Olanzapine LAI; No PDSS Observed - Nasdaq
- 9 months ago - Teva Pharmaceuticals reports completion of phase 3 trial for Olanzapine LAI in Schizophrenia - Seeking Alpha